Farallon Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Farallon Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$234K	–	171
2026 Q1	$234K	Hold	10,000	–	–	﹤0.01%	133
2025 Q4	$210K	Hold	10,000	–	–	﹤0.01%	134
2025 Q3	$154K	Hold	10,000	–	–	﹤0.01%	129
2025 Q2	$93.7K	Hold	10,000	–	–	﹤0.01%	132
2025 Q1	$123K	Hold	10,000	–	–	﹤0.01%	132
2024 Q4	$132K	Hold	10,000	–	–	﹤0.01%	140
2024 Q3	$193K	Hold	10,000	–	–	﹤0.01%	144
2024 Q2	$205K	Hold	10,000	–	–	﹤0.01%	136
2024 Q1	$238K	Hold	10,000	–	–	﹤0.01%	139
2023 Q4	$216K	Buy	+10,000	New	+$154K	﹤0.01%	126

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Farallon Capital Management's SNDX Position: Q2 2026 in Review

Farallon Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 10,000 shares — an estimated $234K sold.

Farallon Capital Management first reported a position in SNDX in Q4 2023 and held it in 10 quarters. The position peaked at $238K in Q1 2024. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Farallon Capital Management reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Farallon Capital Management sold 10,000 Syndax Pharmaceuticals shares in Q2 2026, an estimated $234K.
Farallon Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2023 and held it in 10 quarters.
Farallon Capital Management's Syndax Pharmaceuticals position peaked at $238K in Q1 2024.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.